Daraxonrasib

Significant news in the fight against one of the deadliest cancers: a new oral drug has nearly doubled the median survival of patients with metastatic pancreatic cancer who had already received prior treatment, compared to standard chemotherapy. The drug, Daraxonrasib (RMC-6236), was tested in a phase 3 study called RASolute 302, showing a median overall survival of 13.2 months versus 6.7 months...